pipette
ENEnglish

Enhancing deep sleep with auditory stimulation to boost cognitive training responsiveness in people with Parkinson's disease and mild cognitive impairment: Rationale and design of the double-blind randomized controlled trial PD-CogT-Sleep

A. Ophey, M. T. Kleinsorge, N. A. Wallimann, A. Maric, S. V. Loosli, B. Mollenhauer, B. Balint, R. Huber, C. R. Baumann, E. Kalbe, S. J. Schreiner

PreprintUso en el mundo real

En palabras de los autores

Background: Cognitive training (CogT) is an established non-pharmacological intervention for people with Parkinson's disease (PD) and mild cognitive impairment (PD-MCI). However, overall effects on cognitive outcomes are small to moderate and interindividually highly heterogeneous. Sleep -especially deep sleep- could be an important determinant of CogT responsiveness in PD, and may have beneficial effects on PD pathophysiology. Therefore, the enhancement of deep sleep by phase-targeted auditory stimulation (PTAS) could strengthen the effects of CogT on cognitive symptoms and counteract disease progression. Methods: PD-CogT-Sleep is a monocentric, partly decentralized, double-blind, randomized sham-controlled trial that combines two remotely delivered non-pharmacological interventions, to assess the additive effect of PTAS on digital CogT responsiveness in people with PD-MCI. The primary outcome is executive functions; Secondary and exploratory outcomes include further cognitive functions, participant-reported outcome measures, blood-based biomarkers, and high-density sleep electroencephalography markers. Outcomes are assessed at baseline, five weeks post-allocation and at 3-month follow-up. We aim to consecutively recruit N=50 participants, who will be randomized 1:1 to receive CogT+PTAS or CogT+Sham. Discussion: The PD-CogT-Sleep study integrates wearable and digital technologies to systematically combine a novel, non-invasive, sleep-enhancing intervention (PTAS) with established CogT to improve cognition and evaluate PTAS' disease-modifying potential through its effects on blood-based biomarkers in PD-MCI. The expected results will foster our understanding of the interplay of sleep, cognition, and neurodegeneration, and may guide further development of safe, feasible, scalable, patient-centered, technology-based non-pharmacological interventions counteracting cognitive decline in neurodegenerative diseases.

Resultado principalEl resumen no menciona limitaciones.

Apareció: miércoles, 4 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.02.26367082